AlphaQuest LLC grew its stake in Penumbra, Inc. (NYSE:PEN – Free Report) by 237.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 838 shares of the company’s stock after buying an additional 590 shares during the period. AlphaQuest LLC’s holdings in Penumbra were worth $215,000 at the end of the most recent reporting period. Get Penumbra alerts: A number of other hedge funds and other institut ...

Core Insights - Penumbra's Lightning Flash device demonstrates superiority over traditional blood thinners in treating patients with pulmonary embolism, potentially reshaping treatment protocols [1][3][4] Study Results - The STORM-PE study compared the Lightning Flash device, which combines mechanical clot removal with blood thinners, against anticoagulants alone, showing better outcomes in reducing right heart strain [3][4] - The study's findings could lead to changes in medical guidelines for treating intermediate-high risk pulmonary embolism patients, which have remained unchanged for over a decade [5] Market Implications - The positive results from the study may boost Penumbra's stock, which is currently trading below its 50- and 200-day moving averages, with a buy point identified at 308.99 [4] - Penumbra's device is the only computer-assisted vacuum thrombectomy technology available, indicating a unique market position [7] Patient Treatment Insights - Currently, only 11% to 15% of U.S. pulmonary embolism patients receive mechanical thrombectomy, with over 20% of those treated using Penumbra's device [6] - The Lightning Flash procedure is quicker than traditional blood thinner treatments, taking approximately 56 minutes, with the device active for 25 minutes [9][10] Expert Opinions - Dr. Robert Lookstein, a primary investigator in the study, emphasizes the trial's significance and its potential to change treatment approaches globally [4][11] - Analysts suggest that the STORM-PE study could influence societal guidelines and referral behaviors in treating pulmonary embolism [11]